RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.62

Margin Of Safety %

Put/Call OI Ratio

1.06

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

4.91

Target Price

Analyst Recom

Performance Q

-7.66

Upside

-105.3%

Beta

1.75

Ticker: RGC

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	RGC	8.07	1.36	0.05	6521
2026-10-15	RGC	9.4	1.31	0.37	6634
2026-10-16	RGC	9.63	1.03	0.91	8856
2026-10-19	RGC	10.09	2.14	1.40	4758
2026-10-20	RGC	10.36	1.46	2.25	4309
2026-10-21	RGC	10.87	1.67	0.12	4441
2026-10-22	RGC	9.85	1.63	0.05	4503
2026-10-23	RGC	7.61	1.73	0.01	4406
2026-10-26	RGC	6.75	1.64	0.06	4499
2026-10-27	RGC	7.45	1.52	0.02	4637
2026-10-28	RGC	7.33	1.56	0.00	4590
2026-10-29	RGC	6.83	1.42	0.00	4761
2026-10-30	RGC	6.61	1.40	0.00	4794
2026-11-02	RGC	6.25	1.41	0.00	4786
2026-11-03	RGC	6.1938	1.41	0.00	4787
2026-11-04	RGC	5.39	1.40	0.25	4788
2026-11-05	RGC	5.27	1.37	1.67	4801
2026-11-06	RGC	5.32	1.38	29.00	4818
2026-11-09	RGC	5.595	1.01	2.37	4111
2026-11-10	RGC	5.24	1.03	95.00	4160
2026-11-11	RGC	5.42	1.08	0.95	4254
2026-11-12	RGC	5.14	1.07	0.05	4312
2026-11-13	RGC	5.02	1.06	0.06	4318
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	RGC	8.05	-	-	-
2026-10-15	RGC	9.36	-	-	-
2026-10-16	RGC	9.61	-	-	-
2026-10-19	RGC	10.10	-	-	-
2026-10-20	RGC	10.10	-	-	-
2026-10-21	RGC	10.41	-	-	-
2026-10-22	RGC	9.85	-	-	-
2026-10-23	RGC	7.61	-	-	-
2026-10-26	RGC	6.78	-	-	-
2026-10-27	RGC	7.41	-	-	-
2026-10-28	RGC	7.20	-	-	-
2026-10-29	RGC	6.85	-	-	-
2026-10-30	RGC	6.66	-	-	-
2026-11-02	RGC	6.27	-	-	-
2026-11-03	RGC	6.11	-	-	-
2026-11-04	RGC	5.41	-	-	-
2026-11-05	RGC	5.26	-	-	-
2026-11-06	RGC	5.32	-	-	-
2026-11-09	RGC	5.62	-	-	-
2026-11-10	RGC	5.24	-	-	-
2026-11-11	RGC	5.45	-	-	-
2026-11-12	RGC	5.16	-	-	-
2026-11-13	RGC	4.91	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	RGC	0.00	63.32	1.17
2026-10-15	RGC	0.00	63.32	1.17
2026-10-16	RGC	0.00	63.32	1.17
2026-10-19	RGC	0.00	63.32	1.17
2026-10-20	RGC	0.00	63.32	1.17
2026-10-21	RGC	0.00	63.32	1.17
2026-10-22	RGC	0.00	63.32	1.17
2026-10-23	RGC	0.00	63.32	1.17
2026-10-26	RGC	0.00	63.29	1.17
2026-10-27	RGC	0.00	63.29	0.78
2026-10-28	RGC	0.00	63.29	0.78
2026-10-29	RGC	0.00	63.29	0.78
2026-10-30	RGC	0.00	63.29	0.78
2026-11-02	RGC	0.00	64.45	0.78
2026-11-03	RGC	0.00	64.45	0.78
2026-11-05	RGC	0.00	64.45	0.78
2026-11-06	RGC	0.00	64.45	0.78
2026-11-09	RGC	0.00	63.18	0.78
2026-11-10	RGC	0.00	63.18	0.78
2026-11-11	RGC	0.00	63.18	0.62
2026-11-12	RGC	0.00	63.18	0.62
2026-11-13	RGC	0.00	63.18	0.62
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

63.18

Beta

1.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

94.1

Max Drawdown 5-Year %

-93.9

Target Price

P/E

Forward P/E

PEG

P/S

P/B

183.51

P/Free Cash Flow

EPS

-0.02

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.49

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-94.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare

$4.94

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

18/20

Pullback

15/25

Volume

11/15

Valuation

6/20

TP/AR

2/10

Options

1/10

RSI

34.5

Range 1M

2.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

4/30

Estimates

0/20

Inst/Vol

5/15

Options

5/10

EPS Yr

EPS NY

52W%

0.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

2/30

Growth

0/25

Stability

7/10

LT Trend

4/5

Quality

RGC — P/E HistoricalDrug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings L

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 10

Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

RGC

Latest News

—

Caricamento notizie per RGC…

stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today

news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance

stock history RGC – Regencell Bioscience Holdings Ltd invest stock market

stock prices RGC premarket after hours

ticker RGC fair value insiders trading

TXMD – TherapeuticsMD Inc.

TXMD — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.3

Margin Of Safety %

-24

Put/Call OI Ratio

0.01

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

1.87

Target Price

Analyst Recom

Performance Q

-6.97

Upside

-114.3%

Beta

0.63

Ticker: TXMD

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	TXMD	1.96	0.01	0.00	644
2026-10-15	TXMD	1.925	0.01	0.03	646
2026-10-16	TXMD	1.9	0.01	0.00	677
2026-10-19	TXMD	1.84	0.01	0.00	676
2026-10-20	TXMD	1.91	0.01	0.00	796
2026-10-21	TXMD	1.8721	0.01	0.00	796
2026-10-22	TXMD	1.85	0.01	0.00	796
2026-10-23	TXMD	1.8	0.01	0.00	816
2026-10-26	TXMD	1.81	0.01	0.00	816
2026-10-27	TXMD	1.7999	0.01	0.00	816
2026-10-28	TXMD	1.79	0.01	0.00	816
2026-10-29	TXMD	1.8	0.01	0.00	816
2026-10-30	TXMD	1.8067	0.01	0.00	816
2026-11-02	TXMD	1.7943	0.01	0.00	843
2026-11-03	TXMD	1.79	0.01	0.00	843
2026-11-04	TXMD	1.81	0.01	0.00	843
2026-11-05	TXMD	1.72	0.01	0.00	843
2026-11-06	TXMD	1.695	0.01	0.00	845
2026-11-09	TXMD	1.69	0.01	0.00	905
2026-11-10	TXMD	1.74	0.01	0.00	905
2026-11-11	TXMD	1.86	0.01	0.00	905
2026-11-12	TXMD	1.82	0.01	0.00	905
2026-11-13	TXMD	1.83	0.01	0.00	915
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	TXMD	1.96	-	-	-
2026-10-15	TXMD	1.92	-	-	-
2026-10-16	TXMD	1.90	-	-	-
2026-10-19	TXMD	1.85	-	-	-
2026-10-20	TXMD	1.85	-	-	-
2026-10-21	TXMD	1.91	-	-	-
2026-10-22	TXMD	1.90	-	-	-
2026-10-23	TXMD	1.77	-	-	-
2026-10-26	TXMD	1.82	-	-	-
2026-10-27	TXMD	1.80	-	-	-
2026-10-28	TXMD	1.82	-	-	-
2026-10-29	TXMD	1.81	-	-	-
2026-10-30	TXMD	1.80	-	-	-
2026-11-02	TXMD	1.81	-	-	-
2026-11-03	TXMD	1.81	-	-	-
2026-11-04	TXMD	1.82	-	-	-
2026-11-05	TXMD	1.71	-	-	-
2026-11-06	TXMD	1.69	-	-	-
2026-11-09	TXMD	1.69	-	-	-
2026-11-10	TXMD	1.74	-	-	-
2026-11-11	TXMD	1.86	-	-	-
2026-11-12	TXMD	1.81	-	-	-
2026-11-13	TXMD	1.87	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	TXMD	0.00	-0.76	0.22
2026-10-15	TXMD	0.00	-0.76	0.22
2026-10-16	TXMD	0.00	-0.76	0.22
2026-10-19	TXMD	0.00	-0.76	0.22
2026-10-20	TXMD	0.00	-0.76	0.22
2026-10-21	TXMD	0.00	-0.76	0.22
2026-10-22	TXMD	0.00	-0.76	0.22
2026-10-23	TXMD	0.00	-0.76	0.22
2026-10-26	TXMD	0.00	-0.76	0.22
2026-10-27	TXMD	0.00	-0.76	0.23
2026-10-28	TXMD	0.00	-0.76	0.23
2026-10-29	TXMD	0.00	-0.76	0.23
2026-10-30	TXMD	0.00	-0.76	0.23
2026-11-02	TXMD	0.00	-0.77	0.23
2026-11-03	TXMD	0.00	-0.77	0.23
2026-11-05	TXMD	0.00	-0.77	0.23
2026-11-06	TXMD	0.00	-0.77	0.23
2026-11-09	TXMD	0.00	-0.61	0.23
2026-11-10	TXMD	0.00	-0.61	0.23
2026-11-11	TXMD	0.00	-0.61	0.30
2026-11-12	TXMD	0.00	-0.61	0.30
2026-11-13	TXMD	0.00	-0.61	0.30
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-0.61

Beta

0.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

1.41

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

94.1

Max Drawdown 5-Year %

-97.7

Target Price

P/E

Forward P/E

PEG

P/S

6.62

P/B

0.8

P/Free Cash Flow

6.94

EPS

-0.02

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-6.64

Relative Volume

2.11

Return on Equity vs Sector %

-27.2

Return on Equity vs Industry %

-7.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ TXMD Healthcare

$1.87

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

11/25

Volume

3/15

Valuation

12/20

TP/AR

2/10

Options

8/10

RSI

51.5

Range 1M

53.9%

Sup Dist

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

1/25

Growth

4/30

Estimates

0/20

Inst/Vol

4/15

Options

6/10

EPS Yr

EPS NY

52W%

26.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +52.2% upside

Quality

5/30

Valuation

13/30

Growth

0/25

Stability

6/10

LT Trend

1/5

Upside

+52.2%

Quality

MoS

-24%

TXMD — P/E HistoricalDrug Manufacturers - Specialty & Generic

TherapeuticsMD, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 1

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

TXMD

Latest News

—

Caricamento notizie per TXMD…

stock quote shares TXMD – TherapeuticsMD Inc. Stock Price stock today

news today TXMD – TherapeuticsMD Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch TXMD – TherapeuticsMD Inc. yahoo finance google finance

stock history TXMD – TherapeuticsMD Inc. invest stock market

stock prices TXMD premarket after hours

ticker TXMD fair value insiders trading

EVO – Evotec SE

EVO — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.02

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

-1.02

EPS This/Next Y

1.42

Price

1.58

Target Price

2.47

Analyst Recom

2.33

Performance Q

-19.39

Upside

-1,407.0%

Beta

2.02

Ticker: EVO

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	EVO	1.425	N/A	N/A	0
2026-10-15	EVO	1.415	N/A	N/A	0
2026-10-16	EVO	1.39	N/A	N/A	0
2026-10-19	EVO	1.425	N/A	N/A	0
2026-10-20	EVO	1.485	N/A	N/A	0
2026-10-21	EVO	1.55	N/A	N/A	0
2026-10-22	EVO	1.535	N/A	N/A	0
2026-10-23	EVO	1.51	N/A	N/A	0
2026-10-26	EVO	1.52	N/A	N/A	0
2026-10-27	EVO	1.565	N/A	N/A	0
2026-10-28	EVO	1.605	N/A	N/A	0
2026-10-29	EVO	1.58	N/A	N/A	0
2026-10-30	EVO	1.53	N/A	N/A	0
2026-11-02	EVO	1.52	N/A	N/A	0
2026-11-03	EVO	1.54	N/A	N/A	0
2026-11-04	EVO	1.55	N/A	N/A	0
2026-11-05	EVO	1.74	N/A	N/A	0
2026-11-06	EVO	1.695	N/A	N/A	0
2026-11-09	EVO	1.73	N/A	N/A	0
2026-11-10	EVO	1.69	N/A	N/A	0
2026-11-11	EVO	1.705	N/A	N/A	0
2026-11-12	EVO	1.67	N/A	N/A	0
2026-11-13	EVO	1.57	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	EVO	1.43	-	-	-1.44
2026-10-15	EVO	1.42	-	-	-1.44
2026-10-16	EVO	1.39	-	-	-1.48
2026-10-19	EVO	1.42	-	-	-1.48
2026-10-20	EVO	1.42	-	-	-1.48
2026-10-21	EVO	1.49	-	-	-1.48
2026-10-22	EVO	1.54	-	-	-1.48
2026-10-23	EVO	1.51	-	-	-1.48
2026-10-26	EVO	1.52	-	-	-1.48
2026-10-27	EVO	1.57	-	-	-1.48
2026-10-28	EVO	1.61	-	-	-1.48
2026-10-29	EVO	1.58	-	-	-1.48
2026-10-30	EVO	1.54	-	-	-1.48
2026-11-02	EVO	1.53	-	-	-1.48
2026-11-03	EVO	1.55	-	-	-1.48
2026-11-04	EVO	1.55	-	-	-1.48
2026-11-05	EVO	1.79	-	-	-1.48
2026-11-06	EVO	1.70	-	-	-1.48
2026-11-09	EVO	1.74	-	-	-1.48
2026-11-10	EVO	1.69	-	-	-1.48
2026-11-11	EVO	1.72	-	-	-1.48
2026-11-12	EVO	1.68	-	-	-1.48
2026-11-13	EVO	1.58	-	-	-1.34
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	EVO	0.00	-0.05	0.01
2026-10-15	EVO	0.00	-0.05	0.01
2026-10-16	EVO	0.00	-0.05	0.01
2026-10-19	EVO	0.00	-3.83	0.01
2026-10-20	EVO	0.00	-3.83	0.01
2026-10-21	EVO	0.00	-3.83	0.01
2026-10-22	EVO	0.00	-3.83	0.01
2026-10-23	EVO	0.00	-3.83	0.01
2026-10-26	EVO	0.00	-3.73	0.01
2026-10-27	EVO	0.00	-3.73	0.02
2026-10-28	EVO	0.00	-3.73	0.02
2026-10-29	EVO	0.00	-3.73	0.02
2026-10-30	EVO	0.00	-3.73	0.02
2026-11-02	EVO	0.00	-3.81	0.02
2026-11-03	EVO	0.00	-3.81	0.02
2026-11-05	EVO	0.00	-3.81	0.02
2026-11-06	EVO	0.00	-3.81	0.02
2026-11-09	EVO	0.00	-3.27	0.02
2026-11-10	EVO	0.00	-3.27	0.02
2026-11-11	EVO	0.00	-3.27	0.02
2026-11-12	EVO	0.00	-3.27	0.02
2026-11-13	EVO	0.00	-3.27	0.02
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

Institutional Transactions

-3.27

Beta

2.02

Average Sales Estimate Current Quarter

133

Average Sales Estimate Next Quarter

158

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

93.8

Max Drawdown 5-Year %

-94.6

Target Price

2.47

P/E

Forward P/E

PEG

P/S

0.67

P/B

0.77

P/Free Cash Flow

EPS

-0.59

Average EPS Est. Cur. Y

-1.34

EPS Next Y. (Est.)

0.08

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-25.24

Relative Volume

0.44

Return on Equity vs Sector %

-54.6

Return on Equity vs Industry %

-34.9

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.1

EBIT Estimation

◆ EVO Healthcare

$1.58

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

10/20

Pullback

11/25

Volume

11/15

Valuation

12/20

TP/AR

2/10

Options

0/10

RSI

47.8

Range 1M

47.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

13/30

Estimates

2/20

Inst/Vol

0/15

Options

0/10

EPS Yr

-137.2%

EPS NY

70.1%

52W%

10.2%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +71.2% upside

Quality

2/30

Valuation

16/30

Growth

11/25

Stability

4/10

LT Trend

5/5

Upside

+71.2%

Quality

EVO — P/E HistoricalDrug Manufacturers - Specialty & Generic

Evotec SE

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 4379

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company collaborate with Odyssey Therapeutics, Inc. to designs and develops AI based discovery platform to discover new treatments in autoimmune and inflammatory diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

EVO

Latest News

—

Caricamento notizie per EVO…

stock quote shares EVO – Evotec SE Stock Price stock today

news today EVO – Evotec SE stock forecast ,stock prediction 2023 2024 2025

marketwatch EVO – Evotec SE yahoo finance google finance

stock history EVO – Evotec SE invest stock market

stock prices EVO premarket after hours

ticker EVO fair value insiders trading

EOLS – Evolent Health Inc.

EOLS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

10.39

Margin Of Safety %

Put/Call OI Ratio

0.01

EPS Next Q Diff

0.16

EPS Last/This Y

0.73

EPS This/Next Y

0.35

Price

6.95

Target Price

15.4

Analyst Recom

1.33

Performance Q

-10.42

Upside

-336.4%

Beta

1.34

Ticker: EOLS

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	EOLS	7.22	0.02	0.15	17647
2026-10-15	EOLS	7.57	0.02	0.07	17656
2026-10-16	EOLS	7.14	0.02	0.00	17651
2026-10-19	EOLS	7.36	0.01	5.43	16917
2026-10-20	EOLS	7.36	0.01	0.00	16999
2026-10-21	EOLS	7.41	0.01	0.00	17011
2026-10-22	EOLS	7.4	0.01	0.62	17013
2026-10-23	EOLS	7	0.01	0.20	17003
2026-10-26	EOLS	7.13	0.01	0.00	16991
2026-10-27	EOLS	7.36	0.01	0.00	16992
2026-10-28	EOLS	7.64	0.01	0.00	15993
2026-10-29	EOLS	7.5	0.01	0.00	15796
2026-10-30	EOLS	7.34	0.01	0.01	15806
2026-11-02	EOLS	7.16	0.01	0.91	15348
2026-11-03	EOLS	7.39	0.01	0.00	15368
2026-11-04	EOLS	7.46	0.01	0.00	15640
2026-11-05	EOLS	6.8	0.01	0.15	15691
2026-11-06	EOLS	6.8	0.01	0.00	15687
2026-11-09	EOLS	6.97	0.01	0.00	15692
2026-11-10	EOLS	6.8	0.01	0.00	15703
2026-11-11	EOLS	7.43	0.01	0.00	15725
2026-11-12	EOLS	7.18	0.01	0.00	15721
2026-11-13	EOLS	6.96	0.01	0.15	15721
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	EOLS	7.22	59.4	30.5	-0.05
2026-10-15	EOLS	7.58	59.4	31.0	-0.05
2026-10-16	EOLS	7.09	54.3	30.2	-0.05
2026-10-19	EOLS	7.36	54.3	31.3	-0.05
2026-10-20	EOLS	7.36	54.3	31.3	-0.05
2026-10-21	EOLS	7.35	54.3	31.3	-0.05
2026-10-22	EOLS	7.40	54.3	30.9	-0.05
2026-10-23	EOLS	7.00	54.3	30.9	-0.05
2026-10-26	EOLS	7.18	54.3	31.1	-0.05
2026-10-27	EOLS	7.36	54.3	31.2	-0.05
2026-10-28	EOLS	7.64	54.3	31.6	-0.05
2026-10-29	EOLS	7.51	54.3	30.7	-0.05
2026-10-30	EOLS	7.35	54.3	30.7	-0.05
2026-11-02	EOLS	7.16	54.3	30.6	-0.05
2026-11-03	EOLS	7.37	54.3	30.9	-0.05
2026-11-04	EOLS	7.46	54.3	31.0	-0.05
2026-11-05	EOLS	6.80	54.3	29.9	-0.05
2026-11-06	EOLS	6.80	278.8	27.4	-0.05
2026-11-09	EOLS	6.98	278.8	27.7	-0.05
2026-11-10	EOLS	6.81	278.8	30.2	-0.05
2026-11-11	EOLS	7.43	278.8	31.7	-0.05
2026-11-12	EOLS	7.18	278.8	30.1	-0.05
2026-11-13	EOLS	6.95	152.5	30.1	-0.07
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	EOLS	-1.26	9.53	9.73
2026-10-15	EOLS	-1.26	9.53	9.73
2026-10-16	EOLS	-1.26	9.53	9.73
2026-10-19	EOLS	-1.26	9.52	9.73
2026-10-20	EOLS	-1.26	9.52	9.73
2026-10-21	EOLS	-1.26	9.52	9.73
2026-10-22	EOLS	-1.26	9.52	9.73
2026-10-23	EOLS	-1.26	9.52	9.73
2026-10-26	EOLS	-1.26	7.86	9.73
2026-10-27	EOLS	-1.26	7.86	11.08
2026-10-28	EOLS	-1.26	7.86	11.08
2026-10-29	EOLS	-1.26	7.86	11.08
2026-10-30	EOLS	-1.26	7.86	11.08
2026-11-02	EOLS	-1.26	7.73	11.08
2026-11-03	EOLS	-1.26	7.73	11.08
2026-11-05	EOLS	-1.26	7.73	11.08
2026-11-06	EOLS	-1.26	7.73	11.08
2026-11-09	EOLS	-1.26	7.28	11.06
2026-11-10	EOLS	-1.26	7.28	11.06
2026-11-11	EOLS	-1.26	7.28	10.39
2026-11-12	EOLS	-1.26	7.28	10.39
2026-11-13	EOLS	-1.26	7.28	10.39
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.16

Avg. EPS Est. Current Quarter

0.03

Avg. EPS Est. Next Quarter

Insider Transactions

-1.26

Institutional Transactions

7.28

Beta

1.34

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-77.5

Target Price

15.4

P/E

Forward P/E

21.09

PEG

P/S

1.42

P/B

P/Free Cash Flow

EPS

-0.47

Average EPS Est. Cur. Y

-0.07

EPS Next Y. (Est.)

0.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.56

Relative Volume

0.49

Return on Equity vs Sector %

55.9

Return on Equity vs Industry %

75.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

30.1

◆ EOLS Healthcare

$6.96

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

9/25

Volume

11/15

Valuation

13/20

TP/AR

2/10

Options

8/10

RSI

44.3

Range 1M

42.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

7/25

Growth

25/30

Estimates

2/20

Inst/Vol

5/15

Options

8/10

EPS Yr

92.6%

EPS NY

1115.4%

52W%

57.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +63.8% upside

Quality

7/30

Valuation

14/30

Growth

17/25

Stability

6/10

LT Trend

1/5

Upside

+63.8%

Quality

EOLS — P/E HistoricalDrug Manufacturers - Specialty & Generic

Evolus, Inc. Common Stock

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 365

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

EOLS

Latest News

—

Caricamento notizie per EOLS…

stock quote shares EOLS – Evolent Health Inc. Stock Price stock today

news today EOLS – Evolent Health Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch EOLS – Evolent Health Inc. yahoo finance google finance

stock history EOLS – Evolent Health Inc. invest stock market

stock prices EOLS premarket after hours

ticker EOLS fair value insiders trading

AYTU – Aytu BioPharma Inc.

AYTU — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

3.03

Margin Of Safety %

-17

Put/Call OI Ratio

EPS Next Q Diff

-0.09

EPS Last/This Y

0.79

EPS This/Next Y

0.52

Price

1.79

Target Price

9.67

Analyst Recom

Performance Q

-24.58

Upside

-3,365.4%

Beta

0.22

Ticker: AYTU

23 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-10-14	AYTU	1.97	N/A	N/A	0
2026-10-15	AYTU	2.02	N/A	N/A	0
2026-10-16	AYTU	2	N/A	N/A	0
2026-10-19	AYTU	2.05	N/A	N/A	0
2026-10-20	AYTU	2	N/A	N/A	0
2026-10-21	AYTU	2	N/A	N/A	0
2026-10-22	AYTU	1.97	N/A	N/A	0
2026-10-23	AYTU	1.94	N/A	N/A	0
2026-10-26	AYTU	1.93	N/A	N/A	0
2026-10-27	AYTU	1.91	N/A	N/A	0
2026-10-28	AYTU	1.945	N/A	N/A	0
2026-10-29	AYTU	1.98	N/A	N/A	0
2026-10-30	AYTU	1.97	N/A	N/A	0
2026-11-02	AYTU	1.92	N/A	N/A	0
2026-11-03	AYTU	1.95	N/A	N/A	0
2026-11-04	AYTU	1.87	N/A	N/A	0
2026-11-05	AYTU	1.82	N/A	N/A	0
2026-11-06	AYTU	1.8	N/A	N/A	0
2026-11-09	AYTU	1.81	N/A	N/A	0
2026-11-10	AYTU	1.79	N/A	N/A	0
2026-11-11	AYTU	1.84	N/A	N/A	0
2026-11-12	AYTU	1.785	N/A	N/A	0
2026-11-13	AYTU	1.79	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

23 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-10-14	AYTU	1.99	-92.7	-	-0.36
2026-10-15	AYTU	2.02	-92.7	-	-0.36
2026-10-16	AYTU	2.05	-92.7	-	-0.36
2026-10-19	AYTU	2.00	-92.7	-	-0.36
2026-10-20	AYTU	2.00	-92.7	-	-0.36
2026-10-21	AYTU	2.00	-92.7	-	-0.36
2026-10-22	AYTU	1.97	-92.7	-	-0.36
2026-10-23	AYTU	1.95	-92.7	-	-0.36
2026-10-26	AYTU	1.93	-92.7	-	-0.36
2026-10-27	AYTU	1.90	-92.7	-	-0.36
2026-10-28	AYTU	1.95	-92.7	-	-0.36
2026-10-29	AYTU	1.98	-92.7	-	-0.36
2026-10-30	AYTU	1.96	-92.7	-	-0.36
2026-11-02	AYTU	1.91	-92.7	-	-0.36
2026-11-03	AYTU	1.94	-92.7	-	-0.36
2026-11-04	AYTU	1.87	-92.7	-	-0.36
2026-11-05	AYTU	1.82	-92.7	-	-0.36
2026-11-06	AYTU	1.85	-92.7	-	-0.36
2026-11-09	AYTU	1.79	-92.7	-	-0.36
2026-11-10	AYTU	1.83	-92.7	-	-0.36
2026-11-11	AYTU	1.81	-92.7	-	-0.36
2026-11-12	AYTU	1.82	-92.7	-	-0.36
2026-11-13	AYTU	1.79	-92.7	-	-0.36
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-10-14	AYTU	0.00	-4.61	3.47
2026-10-15	AYTU	0.00	-4.61	3.47
2026-10-16	AYTU	0.00	-4.61	3.47
2026-10-19	AYTU	0.00	-4.50	3.46
2026-10-20	AYTU	0.00	-4.50	3.46
2026-10-21	AYTU	0.00	-4.50	3.46
2026-10-22	AYTU	0.00	-4.50	3.46
2026-10-23	AYTU	0.00	-4.50	3.46
2026-10-26	AYTU	0.00	-4.64	3.46
2026-10-27	AYTU	0.00	-4.64	3.30
2026-10-28	AYTU	0.00	-4.64	3.30
2026-10-29	AYTU	0.00	-4.64	3.30
2026-10-30	AYTU	0.00	-4.64	3.30
2026-11-02	AYTU	0.00	-4.61	3.30
2026-11-03	AYTU	0.00	-4.61	3.30
2026-11-05	AYTU	0.00	-4.61	3.30
2026-11-06	AYTU	0.00	-4.61	3.30
2026-11-09	AYTU	0.00	-4.61	3.30
2026-11-10	AYTU	0.00	-4.61	3.30
2026-11-11	AYTU	0.00	-4.61	3.03
2026-11-12	AYTU	0.00	-4.61	3.03
2026-11-13	AYTU	0.00	-4.61	3.03
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.05

Avg. EPS Est. Current Quarter

-0.18

Avg. EPS Est. Next Quarter

-0.14

Insider Transactions

Institutional Transactions

-4.61

Beta

0.22

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

1.49

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

96.5

Max Drawdown 5-Year %

-98

Target Price

9.67

P/E

Forward P/E

6.59

PEG

P/S

0.34

P/B

0.54

P/Free Cash Flow

5.95

EPS

-1.67

Average EPS Est. Cur. Y

-0.36

EPS Next Y. (Est.)

0.16

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-24.76

Relative Volume

0.54

Return on Equity vs Sector %

-66.8

Return on Equity vs Industry %

-47.1

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.29

EBIT Estimation

◆ AYTU Healthcare

$1.78

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

8/20

Pullback

19/25

Volume

11/15

Valuation

15/20

TP/AR

2/10

Options

0/10

RSI

33.5

Range 1M

10.3%

Sup Dist

2.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

25/30

Estimates

1/20

Inst/Vol

0/15

Options

0/10

EPS Yr

46.3%

EPS NY

143.3%

52W%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +191.1% upside

Quality

5/30

Valuation

19/30

Growth

19/25

Stability

3/10

LT Trend

4/5

Upside

+191.1%

Quality

MoS

-17%

AYTU — P/E HistoricalBiotechnology

Aytu BioPharma, Inc.

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 75

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

AYTU

Latest News

—

Caricamento notizie per AYTU…

stock quote shares AYTU – Aytu BioPharma Inc. Stock Price stock today

news today AYTU – Aytu BioPharma Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch AYTU – Aytu BioPharma Inc. yahoo finance google finance

stock history AYTU – Aytu BioPharma Inc. invest stock market

stock prices AYTU premarket after hours

ticker AYTU fair value insiders trading

RGC – Regencell Bioscience Holdings Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: RGC

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

TXMD – TherapeuticsMD Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: TXMD

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y